Format
Sort by
Items per page

Send to

Choose Destination

Best matches for tazarotene/TU:

Topical Therapies in Psoriasis. Torsekar R et al. Indian Dermatol Online J. (2017)

Pharmacokinetics of tazarotene and acitretin in psoriasis. Heath MS et al. Expert Opin Drug Metab Toxicol. (2018)

Psoriasis. Weigle N et al. Am Fam Physician. (2013)

Search results

Items: 1 to 20 of 426

2.

Novel antipsoriatic fluidized spanlastic nanovesicles: In vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy.

Elmowafy E, El-Gogary RI, Ragai MH, Nasr M.

Int J Pharm. 2019 Sep 10;568:118556. doi: 10.1016/j.ijpharm.2019.118556. Epub 2019 Jul 23.

PMID:
31348982
3.

Risankizumab (Skyrizi) for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jun 3;61(1573):81-83. No abstract available.

PMID:
31170118
4.

Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

Blauvelt A, Green LJ, Lebwohl MG, Yamauchi PS, Lin T, Martin G, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):297-299.

PMID:
30909352
5.

Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis

Kircik LH, Papp KA, Stein Gold L, Harris S, Pharm TL, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):279-284..

PMID:
30909333
6.
7.

Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jan 14;60(1563):4-6. No abstract available.

PMID:
30681661
8.

Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis

Stein Gold L, Bagel J, Lebwohl M, Lin T, Martin G, Pillai R.

J Drugs Dermatol. 2018 Dec 1;17(12):1290-1296.

PMID:
30586261
9.

Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy

Tanghetti E, Lebwohl M, Stein Gold L.

J Drugs Dermatol. 2018 Dec 1;17(12):1280-1287. Review.

PMID:
30586259
10.

Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Therapeutic Intervention.

Shin WJ, Zabel BA, Pachynski RK.

Front Immunol. 2018 Nov 30;9:2772. doi: 10.3389/fimmu.2018.02772. eCollection 2018. Review.

11.

Tazarotene 0.015% Cream as a Potential Topical Agent for Management of Ichthyosis in Dorfman-Chanarin Syndrome.

Niculescu L, Ruini C, Srour J, Salzer S, Schönbuchner I, von Braunmühl T, Ruzicka T, Hohenleutner U, Giehl KA, Fischer J, Wollenberg A.

Acta Derm Venereol. 2019 Mar 1;99(3):345-346. doi: 10.2340/00015555-3087. No abstract available.

12.

Regulation of Chemerin and CMKLR1 Expression by Nutritional Status, Postnatal Development, and Gender.

Sanchez-Rebordelo E, Cunarro J, Perez-Sieira S, Seoane LM, Diéguez C, Nogueiras R, Tovar S.

Int J Mol Sci. 2018 Sep 25;19(10). pii: E2905. doi: 10.3390/ijms19102905.

13.

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.

Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R.

J Am Acad Dermatol. 2019 Jan;80(1):282-285. doi: 10.1016/j.jaad.2018.09.002. Epub 2018 Sep 15. No abstract available.

14.

Pharmacokinetics of tazarotene and acitretin in psoriasis.

Heath MS, Sahni DR, Curry ZA, Feldman SR.

Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):919-927. doi: 10.1080/17425255.2018.1515198. Epub 2018 Sep 3. Review.

PMID:
30134735
15.

Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.

Stein Gold L, Kircik LH, Pariser D, Sugarman JL, Lin T, Kang R, Pillai R.

J Drugs Dermatol. 2018 Aug 1;17(8):863-868.

PMID:
30124725
16.

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.

Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R.

J Drugs Dermatol. 2018 Aug 1;17(8):855-861.

PMID:
30124724
17.

Fractional carbon dioxide laser assisted delivery of topical tazarotene versus topical tioconazole in the treatment of onychomycosis.

Abd El-Aal EB, Abdo HM, Ibrahim SM, Eldestawy MT.

J Dermatolog Treat. 2019 May;30(3):277-282. doi: 10.1080/09546634.2018.1509046. Epub 2018 Sep 28.

PMID:
30081698
18.

Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.

Pariser DM, Green LJ, Stein Gold L, Sugarman JL, Lin T, Pillai R.

J Drugs Dermatol. 2018 Jul 1;17(7):723-726.

PMID:
30005093
19.

Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis.

Dayal S, Kaura R, Sahu P, Jain VK.

An Bras Dermatol. 2018 Jun;93(3):385-390. doi: 10.1590/abd1806-4841.20186723.

20.

Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.

Donigan JM, Hyde MA, Goldgar DE, Hadley ML, Bowling M, Bowen GM.

JAMA Dermatol. 2018 Aug 1;154(8):885-889. doi: 10.1001/jamadermatol.2018.0530.

Supplemental Content

Loading ...
Support Center